-
Mashup Score: 0Debate: PARP Inhibitors for All mCRPC Patients APCCC 2022 Presentation - Noel Clarke - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference, Noel Clarke presents the role of PARP inhibitors for all patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Noel Clarke, MBBS, FRCS, ChM, Professor of Urological Oncology, Salford Royal Hospital & The Christie NHS Foundation Trust, Manchester, UK Related Content: APCCC 2022: Debate: PARP Inhibitors for…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Debate: PARP Inhibitors Only in Selected mCRPC Patients APCCC 2022 Presentation - Johann de Bono - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference, Johann de Bono presents the role of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) patients focusing on the case for a selected, judicious use of PARP inhibitors in this setting. Biographies: Johann de Bono, MD, PhD, Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#Debate: PARP inhibitors only in selected #mCRPC patients. #APCCC22 presentation by @jodebon @ICR_London. #WatchNow on UroToday > https://t.co/kkcKH8YEgD @APCCC_Lugano @silkegillessen @AOmlin @heatherhcheng https://t.co/wNVUH23Pva
-
-
Mashup Score: 0Debate: PARP Inhibitors for All mCRPC Patients APCCC 2022 Presentation - Noel Clarke - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference, Noel Clarke presents the role of PARP inhibitors for all patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Noel Clarke, MBBS, FRCS, ChM, Professor of Urological Oncology, Salford Royal Hospital & The Christie NHS Foundation Trust, Manchester, UK Related Content: APCCC 2022: Debate: PARP Inhibitors for…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#Debate: PARP inhibitors for all #mCRPC patients. #APCCC22 presentation by Noel Clarke, MBBS, FRCS, ChM @TheChristieNHS. #WatchNow on UroToday > https://t.co/qvu8DIdv1b @APCCC_Lugano @silkegillessen @AOmlin https://t.co/hR1obCo0lF
-
-
Mashup Score: 1Debate: PARP Inhibitors Only in Selected mCRPC Patients APCCC 2022 Presentation - Johann de Bono - 2 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference, Johann de Bono presents the role of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) patients focusing on the case for a selected, judicious use of PARP inhibitors in this setting. Biographies: Johann de Bono, MD, PhD, Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#Debate: PARP inhibitors only in selected #mCRPC patients. #APCCC22 presentation by @jodebon @ICR_London. #WatchNow on UroToday > https://t.co/kkcKH8YEgD @APCCC_Lugano @silkegillessen @AOmlin @heatherhcheng https://t.co/x9jNjpl4tL
-
-
Mashup Score: 2Debate: PARP Inhibitors for All mCRPC Patients APCCC 2022 Presentation - Noel Clarke - 2 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference, Noel Clarke presents the role of PARP inhibitors for all patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Noel Clarke, MBBS, FRCS, ChM, Professor of Urological Oncology, Salford Royal Hospital & The Christie NHS Foundation Trust, Manchester, UK Related Content: APCCC 2022: Debate: PARP Inhibitors for…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#Debate: PARP inhibitors for all #mCRPC patients. #APCCC22 presentation by Noel Clarke, MBBS, FRCS, ChM @TheChristieNHS. #WatchNow on UroToday > https://t.co/qvu8DIdv1b @APCCC_Lugano @silkegillessen @AOmlin https://t.co/p8tMmwzelx
-
-
Mashup Score: 4WCET 2022: Debate: Thulium Fiber Laser: Is It "The One"? - 2 year(s) ago
WCET 2022 thulium fiber laser debate, advancements of the thulium laser, comparison of the thulium and holmium lasers, holmium laser is useful in BPH surgery, thulium fiber laser over the holmium laser.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#WCET22 #Debate: Thulium Fiber Laser: Is It "The One"? Presented by Wilson Molina, MD @KHS_Urology. Written coverage by @AllenRojhani @UCI_Urology on UroToday > https://t.co/p9G1DfdWXl @Endo_Society @DrexelMedicine https://t.co/JpFctqirTG
-
-
Mashup Score: 0Members of parliament debate assisted dying in response to a petition calling for a change in the law - 2 year(s) ago
Members of parliament (MPs) in the UK House of Commons have debated the issue of assisted dying after a petition from Dignity in Dying reached more than 155 000 signatures. The petition called on the UK Government to bring forward legislation to allow assisted dying for adults who are terminally ill and are mentally capable of making the decision. Such a move would involve strict safeguards, the…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
News: Members of UK #parliament #debate #assisteddying in response to a petition calling for a change in the law https://t.co/Fj6DGcDy4j
-
-
Mashup Score: 0Debate: ‘Safety, adequacy, cost’ still favor percutaneous vs. endoscopic ultrasound biopsy - 2 year(s) ago
SAN DIEGO — Although percutaneous liver biopsy is still the “gold standard,” advances in techniques and increased use of endoscopic ultrasound-guided biopsy may soon change that dynamic, according to a debate at Digestive Disease Week 2022. “There are several advantages to [endoscopic ultrasound (EUS)-guided liver biopsy], not the least of which is patient comfort,”
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Debate: ‘Safety, adequacy, cost’ still favor percutaneous vs. endoscopic #ultrasound #biopsy #DDW2022 #GITwitter #MedTwitter @DDWMeeting https://t.co/JzZPuSf2fo
-
-
Mashup Score: 2Anthracyclines for patients with early breast cancer - a debate - 2 year(s) ago
Dr Valentina Guarneri, of the istituto Oncologico Veneto, Padova, Italy, and Dr Evandro de Azambuja, of the Institut Jules Bordet and L’Université Libre de Bruxelles, Brussels, Belgium, discuss the pr
Source: SoundCloudCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New #debate podcast by @E_de_Azambuja and Valentina Guarneri - Would you use anthracyclines in the treatment of early #breastcancer @myESMO @cczielinski #ESMOBreast22 #ESMOBreast https://t.co/gO2ZOZkpk3
-
-
Mashup Score: 7APCCC 2022: Debate: Imaging Directed Treatment for BCR - 2 year(s) ago
the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) imaging directed treatment for biochemical recurrent prostate cancer
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#Debate: Imaging directed treatment for BCR. Presentation by @Prof_Nick_James @ICR_London. #APCCC22 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/XvCeMN8Aix @APCCC_Lugano https://t.co/meWNMu0FEK
-
#Debate: PARP inhibitors for all #mCRPC patients. #APCCC22 presentation by Noel Clarke, MBBS, FRCS, ChM @TheChristieNHS. #WatchNow on UroToday > https://t.co/qvu8DIv6pL @APCCC_Lugano @silkegillessen @AOmlin https://t.co/yYpdDqU7rs